Cardiovascular biomarkers predict fragility fractures in older adults

Madeleine Johansson,1 Fabrizio Ricci,1,2 Giuseppe Di Martino,3 Cecilia Rogmark,1,4 Richard Sutton,3 Viktor Hamrefors,1,6 Olle Melander,1,6 Artur Fedorowski1,7

ABSTRACT

Objective To assess the role of four biomarkers of neuroendocrine activation and endothelial dysfunction in the longitudinal prediction of fragility fractures.

Methods We analysed a population-based prospective cohort of 5415 community-dwelling individuals (mean age, 68.9±6.2 years) enrolled in the Malmö Preventive Project followed during 8.1±2.9 years, and investigated the longitudinal association between C-terminal pro-arginine vasopressin (CT-proAVP), C-terminal endothelin-1 precursor fragment (CT-proET-1), the mid-regional fragments of pro-adrenomedullin (MR-proADM) and pro-atrial natriuretic peptide (MR-proANP), and incident vertebral, pelvic and extremity fractures.

Results Overall, 1030 (19.0%) individuals suffered vertebral, pelvic or extremity fracture. They were older (70.7±5.8 vs 68.4±6.3 years), more likely women (46.9% vs 26.3%), had lower body mass index and diastolic blood pressure, were more often on antihypertensive treatment (44.1% vs 38.4%) and had more frequently history of fracture (16.1% vs 8.1%). Higher levels of MR-proADM (adjusted HR (aHR) per 1 SD: 1.51, 95% CI 1.01 to 2.28, p<0.001) and MR-proANP (aHR: 1.23, 95% CI 1.05 to 1.45, p<0.001) were independently associated with increased risk of any fracture. The fracture risk increased linearly across MR-proANP quartiles. Individuals who were in the top quartile of all four biomarkers had a significant higher risk of fracture at any site (aHR: 2.32, 95% CI 1.86 to 2.91), vertebral fracture (aHR: 3.16, 95% CI 1.97 to 5.07) and femoral fracture (aHR: 2.35, 95% CI 1.64 to 3.36).

Conclusions Elevated levels of MR-proADM and MR-proANP independently predict fragility fractures in older adults. In subjects with top quartile levels of all four biomarkers there is a twofold to threefold increase in risk of vertebral and femoral fractures.

INTRODUCTION

Fragility fractures are defined as fractures resulting from relatively mild trauma, such as falling from a standing height or low height of less than 1 m, that healthy adult bones should otherwise be able to withstand.1,2 The main sites of fragility fractures are the thoracolumbar spine, the pelvis, hip and femur, proximalibia, proximal humerus and the distal forearm.3 Fragility fractures account for over 90% of fractures in older people,4 and are often associated with traumatic falls.1

Among fall-predisposing factors, cardiovascular (CV) autonomic dysfunction may lead to circulatory instability, orthostatic intolerance, dizziness, syncope, unexplained falls and traumatic injuries, especially in older people.2,5–7 A previous population-based study demonstrated that CV autonomic dysfunction presenting as orthostatic hypotension (OH), or elevated resting heart rate may predict common fragility fractures.8

In parallel, dysautonomic responses of CV system have been associated with alterations in circulating biomarkers of neuroendocrine activation and endothelial dysfunction such as copeptin, pro-endothelin-1, pro-adrenomedullin and pro-atrial natriuretic peptide.9 These biomarkers have been shown to be elevated in patients with symptomatic OH and cardiac syncope, although downregulated adrenomedullin and endothelin have also been found among patients with cardioinhibitory vasovagal reflex.10–13 Importantly, the increased levels of neuroendocrine activation biomarkers indicate not only risk of incident circulatory collapse and traumatic falls but may point to accompanying endothelial dysfunction and structural CV changes.14 Taken together, assessment of these biomarkers may be useful to detect covert disorders of CV system predisposing to orthostatic intolerance and syncope, as well as endothelial dysfunction and chronic inflammation, all of which indicate higher risk of fragility fractures in older people.6,15 Accordingly, our aim was prospectively to investigate the relationship between circulating levels of precursor fragments of four bioactive peptides: adrenomedullin, arginine-vasopressin, atrial-natriuretic-peptide and endothelin-1, and incidence of fragility fractures in community-dwelling older middle-aged subjects.

METHODS

Study design and population

The Malmö Preventive Project (MPP) is a large prospective population-based cohort study including 33 346 citizens of Malmö, Sweden, who were enrolled in 1974–1992 (33% women, mean age at enrolment 45 years; range 26–61 years).16 A total of 18 240 among approximately 25 870 surviving participants (age, 68 years; participation rate, 70.3%) attended a rescreening programme between 2002 and 2006, consisting of complete physical examination, self-administered questionnaire exploring medical history including level of physical activity (1—sedentary leisure time; 2—moderate exercise during leisure time; 3—regular exercise and training; 4—intensive or professional

training) and fasting blood sampling. The details regarding the rescreening programme can be found elsewhere. The study complied with the Declaration of Helsinki, and all participants gave informed written consent.

**CV biomarkers**

We investigated four haemodynamically active CV biomarkers: C-terminal pro-arginine vasopressin (CT-proAVP; a stable peptide of the arginine vasopressin precursor), C-terminal endothelin-1 precursor fragment (CT-proET-1), the mid-regional fragments of pro-adrenomedullin (MR-proADM) and pro-atrial natriuretic peptide (MR-proANP) among randomly selected 5415 study participants. Plasma biomarkers were measured in fasting blood samples that had been frozen at −80°C after collection during rescreening examination in years 2002–2006. Circulating levels of CT-proAVP, CT-proET-1, MR-proADM and MR-proANP were used as the following assays according to the manufacturer’s instructions: Thermo Scientific B-R-A-H-M-S CT-proAVP LIA, Thermo Scientific B-R-A-H-M-S CT-proET-1 KRYPTOR, Thermo Scientific B-R-A-H-M-S MR-proADM KRYPTOR and Thermo Scientific B-R-A-H-M-S MR-proANP KRYPTOR (BRAHMS, Hennigsdorf, Germany).

| Table 1 Baseline characteristics of the study population (n=5415) |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Characteristics | Overall (n=5415) | Fracture positive (n=1030) | Fracture negative (n=4385) | P values |
| Age (years) | 68.9±6.2 | 70.7±5.8 | 68.4±6.3 | <0.001 |
| Sex (% male) | 69.7 | 53.1 | 73.7 | <0.001 |
| BMI (kg/m²) | 22.3±3.7 | 22.7±3.9 | 23.4±3.7 | <0.001 |
| Current smoker, n (%) | 855 (15.8) | 175 (17.0) | 680 (15.5) | 0.24 |
| Supine systolic BP (mm Hg) | 145.7±20 | 144.7±20.6 | 146.0±20.5 | 0.076 |
| Supine diastolic BP (mm Hg) | 83.8±10.8 | 82.9±10.7 | 84.0±10.8 | 0.003 |
| Heart rate (bpm) | 70.9±12.3 | 71.1±12.5 | 70.9±12.2 | 0.76 |
| Antihypertensive treatment, n (%) | 2137 (39.5) | 454 (44.1) | 1683 (38.4) | 0.001 |
| Prevalent fracture, n (%) | 524 (9.7) | 168 (16.3) | 356 (8.1) | <0.001 |
| Diabetes, n (%) | 673 (12.4%) | 134 (13) | 539 (12.3) | 0.48 |
| CT-proAVP (pmol/L) | 9.6±11 | 9.46±8.92 | 9.66±11.9 | 0.61 |
| CT-proET (pmol/L) | 71.2±20 | 75.3±22.1 | 70.6±19.4 | 0.001 |
| MR-proADM (nmol/L) | 0.75±0.23 | 0.79±0.27 | 0.74±0.23 | <0.001 |
| MR-proANP (pmol/L) | 125.5±82.8 | 138.1±88.3 | 122.5±81.2 | <0.001 |

Values are mean±SD unless otherwise indicated. BMI, body mass index; BP, blood pressure; CT-proAVP, copeptin; CT-proET-1, C-terminal endothelin-1; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide.

**Fracture data**

Fractures, which are of typical location for fragility injuries in elderly, served as the primary endpoint for the assessment of fall risk relative to the alterations in the assessed CV biomarkers. Fractures were defined according to International Classification of Diseases (ICD), 10th Revision. Information about fracture diagnoses (date and ICD-10 code) and the date of death have been retrieved from the Swedish National Hospital Discharge Register and the Swedish National Cause of Death Register covering the period from MPP rescreening date, that is, 21 January 2002 to 21 December 2006 until 31 December 2014. In this study, we included fractures affecting spine and thoracic cage (S12.x, S22.x, S32.x), arms, shoulders and hands (S42.x, S52.x and S62.x), pelvis (S32.x), as well as hips and femur (S72.x). In addition, codes signalling stress fractures or similar were also sought (M48.4, M84.3 and M96.6).

**Statistical analysis**

Group differences in continuous variables between fracture-positive and fracture-negative individuals were compared using one-way analysis of variance test, whereas group differences in categorical variables were compared using Pearson’s X² test. The distribution of all four biomarkers was right skewed and log transformation was performed. The log-transformed and standardised values of CT-proAVP, CT-proET-1, MR-proADM and MR-proANP were used as independent variables for Cox regression analysis. The multivariable adjusted model was built and MR-proANP were used as independent variables for Cox regression analysis. The proportional hazards assumption was assessed plotting log-log survival curves of all predictors inserted in the model. If the curves remained approximately parallel, the proportional hazards assumption was satisfied. The Harrell’s C-statistic was computed to evaluate overall adequacy of risk prediction procedures. We also tested presence of interaction between age, sex and antihypertensive therapy on the relationship between each CV biomarker and fracture risk. Additionally, we performed sensitivity analysis by fracture site, where in order to allow adequate multivariable adjustment we restricted the analysis to those subtypes with incidence > 100 cases. Finally, we performed Fine and Gray proportional hazards models to estimate sub-HRs of CV biomarkers controlling for death as competing event. C-statistic was also computed for competing risk models. All analyses were performed using SPSS Statistics V24.0.0.1 (IBM) or SAS V9.2. Only findings with a two-tailed p value <0.05 were considered significant.

**RESULTS**

During the follow-up period of 8.1±2.9 years, a total of 1030 study participants (19.0%) suffered either vertebral, thoracic, arm, pelvic, hip or femoral fractures. Patients with incident fracture were older, more likely women, had lower BMI, diastolic BP, and had more often antihypertensive treatment and history of fracture compared with fracture-free participants (table 1).

In the fully adjusted Cox regression model (table 2), higher levels of MR-proADM (adjusted HR (aHR) per 1 SD: 1.51, 95% CI 1.01 to 2.28, p<0.001) and MR-proANP (aHR: 1.23, 95% CI 1.05 to 1.45, p<0.001) were independently associated with increased risk of fragility fractures. Adjusted Cox model satisfied the proportional hazards assumption. Further, as shown in figure 1A–D and online supplementary table S5, the cumulative risk of incident fractures increased linearly from lowest to highest quartile of MR-proANP, with a significant trend across quartiles of CT-proET-1 and MR-proADM. As regards CT-proAVP, the fracture risk was similarly elevated in both the lowest and highest quartiles, compared with the two mid-quartiles; however, after full adjustment, the association with
Table 2  Risk of incident fragility fractures in a population of 5415 older adults according to circulating levels of cardiovascular biomarkers, CT-proAVP, CT-proET-1, MR-proADM and MR-proANP, in a Cox regression model

<table>
<thead>
<tr>
<th>Biomarkers</th>
<th>Unadjusted</th>
<th>Adjusted for age and gender</th>
<th>Fully adjusted*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI)†</td>
<td>C-statistic</td>
<td>HR (95% CI)†</td>
</tr>
<tr>
<td>CT-proAVP</td>
<td>0.99 (0.93 to 1.06)</td>
<td>0.504 (0.432–0.611)</td>
<td>1.06 (0.99 to 1.13)</td>
</tr>
<tr>
<td>CT-proET-1</td>
<td>1.30 (1.23 to 1.39)</td>
<td>0.574 (0.448–0.698)</td>
<td>1.19 (1.11 to 1.28)</td>
</tr>
<tr>
<td>MR-proADM</td>
<td>1.37 (1.29 to 1.45)</td>
<td>0.577 (0.450–0.693)</td>
<td>1.21 (1.13 to 1.29)</td>
</tr>
<tr>
<td>MR-proANP</td>
<td>1.34 (1.26 to 1.43)</td>
<td>0.580 (0.455–0.698)</td>
<td>1.19 (1.11 to 1.28)</td>
</tr>
</tbody>
</table>

*Adjusted for age, gender, body mass index, systolic blood pressure, heart rate, antihypertensive treatment, diabetes, smoking, prevalent fractures, history of cardio/cerebrovascular disease and self-reported physical activity.

CT-proAVP, copeptin; CT-proET-1, C-terminal endothelin-1; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide.

CT-proAVP was no longer significant (Q1–Q4 vs Q2–Q3, aHR: 1.03, 95% CI 0.95 to 1.10). Higher level of CT-proET-1 independently predicted femoral fracture only (aHR: 1.17, 95% CI 1.01 to 1.35) (online supplementary table S8).

Individuals who were in the top quartile of all four biomarkers (n=324) had a significantly higher risk of fracture at any site (aHR: 2.32, 95% CI 1.86 to 2.91), vertebral fracture (aHR: 3.16, 95% CI 1.97 to 5.07) and femoral fracture (aHR: 2.35, 95% CI 1.64 to 3.36) (table 3).

There were significant interactions between sex and all four CV biomarkers, between age and MR-proANP, and between antihypertensive treatment and CT-proAVP, for incident fracture risk (online supplementary tables S1–S4). In particular, the relationship with incident fractures appeared to be stronger for men with elevated levels of MR-proANP, MR-proADM and CT-proET-1, for women with elevated levels of CT-proAVP (online supplementary table S2), for older participants with elevated MR-proANP (online supplementary table S3) and for...
patients on antihypertensive treatment with elevated CT-proAVP (online supplementary table S4).

**DISCUSSION**

In this study, two biomarkers of neuroendocrine activation and endothelial dysfunction, MR-proADM and MR-proANP, independently predicted fragility fractures in older adults. Moreover, the combination of top quartiles of CT-proAVP, CT-proET-1, the MR-proADM and MR-proANP was independently associated with a twofold to threefold increase in risk of incident fractures, mostly at femoral and vertebral sites.

The assessed biomarkers have been previously found to predict adverse outcomes in patients with established CV disease such as coronary ischaemia or heart failure. Here, we have demonstrated that higher levels of these biomarkers may also predict fragility fractures in older people. Importantly, the strongest relationship was observed for MR-proADM and MR-proANP.

**Mid-regional fragment of pro-adrenomedullin**

MR-proADM is a precursor fragment of adrenomedullin with strong vasodilating properties. As previously reported, the plasma concentration of MR-proADM is significantly higher among patients with cardiac syncope (eg, primary cardiac arrhythmia and structural heart disease) as well as in syncope due to OH. Increased MR-proADM levels were also found in patients with carotid sinus hypersensitivity, OH and unexplained syncope after initial evaluation, suggesting presence of either CV autonomic dysfunction or paroxysmal arrhythmia with or without underlying structural heart disease as the potential cause of fall trauma. However, adrenomedullin has other, apart from circulatory, properties such as regulation of insulin and bone metabolism. In particular, higher levels of adrenomedullin have been associated with osteoporosis, whereas treatment with adrenomedullin inhibitor has been related to increased bone density in animal models.

**Mid-regional pro-atrial natriuretic peptide**

MR-proANP is a precursor fragment of vasodilating and diuretic hormone that controls vascular permeability and contractility, renin and aldosterone secretion, sympathetic nerve activity and renal tubular sodium transport. Elevated levels of MR-proANP have been linked to delayed OH. Earlier studies have suggested that MR-proANP levels may serve as a marker of cardiac syncope. Sabatine et al showed that MR-proANP and MR-proADM were, in fact, superior to N-terminal pro-brain natriuretic peptide in predicting negative outcomes in chronic coronary disease. Thus, higher levels of ANP may predict susceptibility to OH, cardiac syncope and, consequently, to increased fall risk. Although primarily active in the CV system, presence of ANP has been detected in human cartilage, suggesting that this neuropeptide may also be involved in bone and cartilage metabolism, pointing at other than circulatory mechanisms behind ANP-fragility fracture association.

The upregulation of CV hormones may indicate a susceptibility to develop manifest CV autonomic failure, OH and cerebral hypoperfusion, thus increasing the risk of traumatic falls. Interestingly, the higher likelihood of fracture was independently predicted by increasing levels of vasodilating biomarkers, MR-proADM and MR-proANP, but not by vasoconstrictors, CT-proAVP and CT-proET-1. A possible explanation could be that higher levels of circulating vasodilators decrease the ability to buffer wide fluctuations in BP and autoregulation of cerebral blood flow during orthostasis, shifting central blood volume to the periphery. Notably, combination of highest levels of all four biomarkers identified subjects with the highest likelihood of incident fracture, suggesting additive effect of information conferred by each of four biomarkers.

One might argue that higher levels of CV biomarkers could also predict CV events such as acute coronary events and cardiac arrhythmia, so, other than dysautonomic mechanisms may have been involved in traumatic falls. In fact, lower bone mineral density, implicating higher susceptibility to fragility fractures, is associated with increased coronary calcification index and risk of coronary disease. Although the design of our study does not allow detailed analysis of all fracture scenarios, it is estimated that primary cardiac arrhythmias are responsible for about 10%–15% cases of unexplained syncope, and, probably, a similar proportion of unexplained falls. Thus, the assessed biomarkers may herald risk of circulatory collapse due to autonomic dysfunction and primary heart disease, especially in regard to increased MR-proANP. However, syncope due to autonomic disorders, reflex syncope and OH are much more frequent than primary cardiac disease.

To give a balanced view of the reported association between increased levels of haemodynamically active hormones and the incidence of fragility fractures, we might consider an alternative scenario where the biomarkers of endothelial dysfunction indicate microvascular disorders in bone tissue leading to

| Table 3 Risk of incident fragility fractures in patients in the fourth quartiles of cardiovascular biomarkers (CT-proAVP, CT-proET-1, MR-proADM and MR-proANP) in multivariable Cox regression model |
|------------------|------------------|------------------|------------------|------------------|------------------|
|                  | Fracture at any site | Vertebal (n=104) | Upper (n=118)  | Forearm (n=153) | Femoral (n=312) |
| C-statistic (95% CI) | Reference | Reference | Reference | Reference | Reference |
| No biomarker in Q4 | 0.656 (0.550 to 0.789) | 0.659 (0.497 to 0.791) | 0.641 (0.486 to 0.786) | 0.645 (0.490 to 0.780) | 0.648 (0.501 to 0.790) |
| One biomarker in Q4 | 1.03 (0.67 to 1.10) | 0.76 (0.33 to 1.51) | 0.55 (0.13 to 1.02) | 0.75 (0.43 to 1.33) | 0.76 (0.46 to 1.23) |
| Two biomarkers in Q4 | 1.36 (1.05 to 1.76) | 2.16 (1.21 to 3.86) | 1.20 (0.67 to 2.16) | 1.47 (0.88 to 2.45) | 1.54 (0.98 to 2.40) |
| Three biomarkers in Q4 | 1.26 (0.92 to 1.64) | 2.01 (1.07 to 3.39) | 1.13 (0.63 to 2.03) | 0.78 (0.35 to 1.13) | 0.98 (0.45 to 1.44) |
| Four biomarkers in Q4 | 2.32 (1.86 to 2.91) | 3.16 (1.97 to 5.07) | 1.18 (0.67 to 2.08) | 0.83 (0.44 to 1.58) | 2.35 (1.64 to 3.36) |

Adjusted for age, gender, body mass index, systolic blood pressure, heart rate, antihypertensive treatment, smoking, diabetes, prevalent fractures, history of cardio/ cerebrovascular disease and physical activity. Only fracture sites with incidence over 100 cases were analysed.

Q4, fourth quartile.
bone fragility. The pathophysiological mechanisms underlying bone fragility in older people are complex and both reduced resistance to stress and increased risk of falling contribute to fragility fractures, as observed in diabetes mellitus.28 Accordingly, CV biomarkers may confer information about both global neuroendocrine hyperactivation and microvascular endothelial dysfunction and point to a synergic effect of CV imbalance and circulatory-mediated fall risk associated with negative alterations in bone structure.

In a subgroup analysis, the observed relations of MR-proADM and MR-proANP with fragility fractures were stronger in men, who were, however, over-represented in the study sample (=70%). Another potential explanation could be an important impact of menopause on bone fragility in women, a factor that is not present in men. Consequently, haemodynamic and metabolic pathological mechanisms signalled by increased levels of CV biomarkers may play a more important role in older middle-aged men than in postmenopausal women.

As the population of older individuals increases, the absolute number of fragility fractures is also expected to rise.30 31 Lagi et al showed that almost 30% of older patients without memory deficit had difficulties recalling a minor fall after 3 months.32 Considering that nearly 50% of cases are not witnessed, markers that could exclude or confirm orthostatic instability and syncope would be of great value. It might be even more important to identify older adults who demonstrate higher risk of fragility fractures and apply CV biomarkers for risk stratification and possible prophylactic strategies such as more restrictive use of fall-risk-increasing drugs32 and home adaptations.

Strengths and limitations

The principal strengths of this work were the large study population and extensive follow-up time, as well as reliable data registers. Nevertheless, we recognise some limitations that should be addressed. First, we acknowledge the lack of prospective biomarker assessment during follow-up as well as lack of important pieces of information such as calcium and phosphorus metabolism, bone mineral density, vitamin D levels and use of medications—other than antihypertensive drugs—with potential adverse effects on orthostatic stability, alertness, balance and neuroendocrine activation. Second, although we performed adjustments for multiple potential confounders, we cannot exclude possibility of residual confounding not accounted for by available covariates. Thus, the differences in biomarker levels might also be due to the fact that fragility fracture-prone individuals are of poorer general health compared with the rest of cohort. Third, in competing risk analysis controlling for death, MR-proADM and MR-proANP lost their significant association with fragility fractures, while higher levels of MR-proANP showed non-significant tendency towards increased fracture risk in fully adjusted model (aHR: 1.23, 95%CI 0.99 to 1.38, p=0.06) (online supplementary tables S6 and S7). Fourth, register-derived fracture codes may have included a smaller number of high-energy fractures but they were presumably evenly distributed among the groups. Finally, we hypothesised that the majority of fragility fractures resulted from a fall due to diminished cerebral perfusion, although low-energy fractures may occur in other situations such as tripping or slipping.

CONCLUSIONS

Higher levels of MR-proADM and MR-proANP predict incident fragility fractures in older adults. In subjects with top quartile levels of the four biomarkers there was a twofold to threefold increase in risk of incident fracture, mostly involving vertebral and femoral sites. Further research is needed to assess the utility of CV biomarkers in understanding and prevention of fragility fractures.
Cardiac risk factors and prevention


